The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial

Cook, G; Royle, K-L; O'Connor, S; Cairns, DA; Ashcroft, AJ; Williams, CD; Hockaday, A; ... National Cancer Research Institute Haemato-oncology Clinical Stu, ; + view all Cook, G; Royle, K-L; O'Connor, S; Cairns, DA; Ashcroft, AJ; Williams, CD; Hockaday, A; Cavenagh, JD; Snowden, JA; Ademokun, D; Tholouli, E; Andrews, VE; Jenner, M; Parrish, C; Yong, K; Cavet, J; Hunter, H; Bird, JM; Pratt, G; Drayson, MT; Brown, JM; Morris, TCM; National Cancer Research Institute Haemato-oncology Clinical Stu, ; - view fewer (2019) The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. British Journal of Haematology 10.1111/bjh.15782 . (In press). Green open access

http://bit.ly/2tjOqF5